Notice NOT-CA-24-109 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-25-080 from the NIH Guide for Grants and Contracts. The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers.

Notice NOT-NS-24-132 from the NIH Guide for Grants and Contracts

Notice NOT-GM-24-053 from the NIH Guide for Grants and Contracts

Notice NOT-GM-24-052 from the NIH Guide for Grants and Contracts

Notice NOT-GM-24-051 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-25-013 from the NIH Guide for Grants and Contracts. The overall goal of this UG3/UH3 Exploratory/Developmental phased initiative is to support the discovery and development of novel natural products that are safe, nontoxic, and efficacious for cancer interception and prevention. 1. Purpose of UG3: Select clinically relevant targets and develop and validate assays for bioactivity as well as toxicity screening 2. Purpose of UH3 phase: Screening libraries, structure elucidation, full-scale characterization, efficacy testing, and development of the screened agents.

Notice NOT-DA-24-047 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-005 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-24-294 from the NIH Guide for Grants and Contracts. Reissue PAR-21-233 - The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

Funding Opportunity PAR-24-293 from the NIH Guide for Grants and Contracts. The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

Notice NOT-NR-25-001 from the NIH Guide for Grants and Contracts

GBP 46,148.00 - 52,809.00 per year: Leeds Teaching Hospitals: Job summary Applications are invited to join the newlyestablished Scientific Computing Group at Leeds Teaching Hospitals NHSTrust. This job offers an Leeds, United Kingdom

Funding Opportunity PAR-25-061 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications from eligible academic and research institutions to apply for funding to modernize existing or construct new biomedical research facilities. Applications will be accepted from public and private nonprofit institutions of higher education, as well as from non-profit research organizations. Applications from both research-intensive institutions and Institutions of Emerging Excellence(IEE) in biomedical research from all geographic regions in the nation are strongly encouraged. NIH recognizes the importance of all institutions of higher learning in contributing to the nations research capacity from either research-intensive or low-resourced institutions. The goal of this NOFO is to modernize biomedical research infrastructure to strengthen biomedical research programs. Each project is expected to produce substantial long-term improvements to the institutional research infrastructure. Intended projects are the construction or modernization of core facilities and the development of other shared research infrastructure serving an institution-wide research community with broad impact on biomedical research.

Notice NOT-GM-24-055 from the NIH Guide for Grants and Contracts

Notice NOT-NR-24-012 from the NIH Guide for Grants and Contracts

Notice NOT-OD-24-178 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-26-010 from the NIH Guide for Grants and Contracts. To promote research investigating protective and pathogenic mechanisms at the nexus of mitochondria function and aging in the context of HIV infection and exposure to addictive substances. We anticipate this foundational knowledge could be leveraged to develop targeted therapies and improve outcomes in people aging with HIV, substance use and addiction.

Funding Opportunity RFA-DA-26-009 from the NIH Guide for Grants and Contracts. To promote research investigating protective and pathogenic mechanisms at the nexus of mitochondria function and aging in the context of HIV infection and exposure to addictive substances. We anticipate this foundational knowledge could be leveraged to develop targeted therapies and improve outcomes in people aging with HIV, substance use and addiction.

Competitive: Genomics England: Company Description Genomics England partners with the NHS to provide whole genome sequencing diagnostics. We also equip researchers to find the caus London, United Kingdom